Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A genetic disorder that affects the ability of the body to effectively break down fat from our diet. It is typically characterized by hypotonia (low muscle tone) and seizures in the newborn period. Other symptoms include unusual facial features and an enlarged liver (hepatomegaly). Most babies with this condition nevergain anydevelopmental skills and do not survive past the age of 2. DBP deficiency is caused by mutations in the HSD17B4 gene and is inherited in an autosomal recessive manner. Some researchers have suggested classifying DBP deficiency into three subtypes, depending on how severely the mutation in the HSD17B4 gene affects the function of the gene and the protein that it codes for. Almost all individuals with types I, II, and III have similar signs and symptoms. A fourth subtype has additionally been proposed for individuals that have less severe symptoms. While there is no cure for DBP deficiency, treatment is focused on improving nutrition and growth, controlling symptoms, and limiting the progression of liver disease.
Features include always present findings: Bilateral tonic-clonic seizure, Low muscle tone (hypotonia), Increased circulating very long-chain fatty acid concentration, and Global developmental delay and others; and very common findings: Seizure, Scaphocephaly, and Neonatal hypotonia. 60 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 8 | Bilateral tonic-clonic seizure, Seizure, Cerebral hypoplasia |
Digestive system | 7 | Hepatic steatosis, Cholestasis, Fetal ascites |
Muscles | 5 | Decreased muscle mass, Low muscle tone (hypotonia), Shrinkage of the cerebellum (cerebellar atrophy) |
Eyes | 2 | Strabismus, Nystagmus |
Lab test results | 2 | Increased circulating very long-chain fatty acid concentration, Elevated circulating hepatic transaminase concentration |
Bones and joints | 2 | Delayed skeletal maturation, Mild bone density loss (osteopenia) |
Pregnancy and birth | 2 | Fetal ascites, Neonatal hypotonia |
Head and neck | 2 | High palate, Macrocephaly |
Ears | 1 | Hearing loss (hearing impairment) |
Arms and legs | 1 | Split hand |
Hormones | 1 | Primary adrenal insufficiency |
Growth and development | 1 | Failure to thrive |
Blood and immune system | 1 | Enlarged spleen (splenomegaly) |
Kidneys and urinary system | 1 | Renal cyst |
Age of onset: newborn period.
HSD17B4 encodes hydroxysteroid 17-beta dehydrogenase 4 (736 aa). Bifunctional enzyme acting on the peroxisomal fatty acid beta-oxidation pathway. Highest expression in Thyroid (203.8 TPM) and Adrenal Gland (129.8 TPM).
D-bifunctional protein deficiency is caused by mutations in the HSD17B4 gene on chromosome 5.
The HSD17B4 protein participates in HSD17B4 dehydrogenates 3-hydroxyhexacosanoyl-CoA, HSD17B4 hydrates trans-2,3-dehydrohexacosanoyl-CoA, and Hydration of delta2-tetracosaheptaenoyl-CoA to 3-hydroxy tetracosahexaenoyl-CoA pathways.
HSD17B4 is classified as a druggable target (Druggable Genome, Enzyme, and Short Chain Dehydrogenase Reductase categories) with score 0.0.
Genetic testing for HSD17B4 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 7 always present features, 3 very common features, 30 common features.
2 clinical trials registered, 1 recruiting. Interventions under study include drug therapy, other interventions, and biologic therapy. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
23 publications have been identified in PubMed for d-bifunctional protein deficiency. Research spans Case Report / Case Series (48%), Basic Science / Preclinical (35%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 11 | 48% |
Laboratory research | 8 | 35% |
Research summaries | 3 | 13% |
Disease patterns and progression | 1 | 4% |
Wang J (2026). [PMID: 42219416](https://pubmed.ncbi.nlm.nih.gov/42219416/). *Cell Mol Life Sci*. [Basic Science / Preclinical]
Erdal AE (2026). [PMID: 40416444](https://pubmed.ncbi.nlm.nih.gov/40416444/). *Molecular syndromology*. [Case Report / Case Series]
Wang W (2026). [PMID: 41765062](https://pubmed.ncbi.nlm.nih.gov/41765062/). *Mitochondrion*. [Basic Science / Preclinical]
Shokouhian E (2026). [PMID: 39847269](https://pubmed.ncbi.nlm.nih.gov/39847269/). *J Appl Genet*. [Review / Meta-Analysis]
Diaz-Moreno U (2026). [PMID: 41367148](https://pubmed.ncbi.nlm.nih.gov/41367148/). *Journal of inherited metabolic disease*. [Case Report / Case Series]
Ahmad N (2026). [PMID: 41525964](https://pubmed.ncbi.nlm.nih.gov/41525964/). *Clinica chimica acta; international journal of clinical chemistry*. [Case Report / Case Series]
Liu H (2025). [PMID: 41282484](https://pubmed.ncbi.nlm.nih.gov/41282484/). *Frontiers in genetics*. [Case Report / Case Series]
Thomas HB (2025). [PMID: 40043708](https://pubmed.ncbi.nlm.nih.gov/40043708/). *American journal of human genetics*. [Basic Science / Preclinical]
Bae JE (2025). [PMID: 40102401](https://pubmed.ncbi.nlm.nih.gov/40102401/). *Nature communications*. [Basic Science / Preclinical]
Long X (2025). [PMID: 40410890](https://pubmed.ncbi.nlm.nih.gov/40410890/). *Human genomics*. [Review / Meta-Analysis]
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 6:54 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center